Oto acoustic emissions in early detection of sensorineural hearing loss in high-risk neonates
Keywords:OAE, ABR, BERA, Hearing loss, High risk babies, Neonate screening
Background: Early identiﬁcation of congenital hearing loss and early intervention ameliorated many adverse consequences. This study was performed to observe effectiveness of otoacoustic emission in screening of hearing loss in high-risk babies.
Methods: Prospective study on 45 high-risk newborns delivered during period of 2013-2014. Selective newborn hearing performed with oto acoustic emissions (OAE) and auditory brain stem responses (ABR), in high-risk infants aged below 7 days, 15 days, after 45 days and after 90 days.
Results: Study population comprised of 45 high-risk newborns. In 1st level screening, 28 (62%) babies showed recordable OAE, 17 (38%) babies failed. In 2nd level screening 31 (81%) passed and 7 (19%) failed and death occurred in 7 infants. In 3rd level screening both OAE and brain stem evoked response audiometry (BERA), was performed in 38 cases and positivity was reported in 37 cases. 4th level screening was similar to 3rd level screening where 3 babies failed ABR test. In our study incidence of sensorineural hearing loss found to be 78.91% (3/38×1000) per 1000 high-risk babies. Auditory neuropathy was observed in 2 (4.4%) patients. Sensitivity and specificity of OAE was 100% and 33.3% respectively. In high-risk low birth weight neonates’ sensitivity and specificity was 66.7% and 50.0%.
Conclusions: In high-risk babies, appropriate time for screening with OAE is around 60 days of age. OAE are useful diagnostic tool in evaluation of high-risk neonates for early detection of sensorineural hearing loss.
Sininger YS, Doyle KJ, Moore JK. The case for early identification of hearing loss in children: auditory system development, experimental auditory deprivation, and development of speech perception and hearing. Pediatr Clin N Am. 1999;46(1):1-4.
Xoinis K, Weirather Y, Mavoori H, Shaha SH, Iwamoto LM. Extremely low birth weight infants are at high risk for auditory neuropathy. J Perinatol. 2007;27(11):718-23.
Davis A, Wood S. The epidemiology of childhood hearing impairment: Factors relevant to planning of services, Bri J audiol. 1992;26:77-90.
Johnson JL, White KR, Widen JE, Gravel JS, James M, Kennalley T et al. A multicenter evaluation of how many infants with permanent hearing loss pass a two-stage otoacoustic emissions/automated auditory brainstem response newborn hearing screening protocol. Pediatrics. 2005;116(3):663-72.
Owens JJ, McCoy MJ, Lonsbury-Martin BL, Martin GK. Otoacoustic emissions in children with normal ears, middle ear dysfunction, and ventilating tubes. Am j otol. 1993;14(1):34-40.
Galambos R, Despland PA. The auditory brainstem response (ABR) evaluates risk factors for hearing loss in the newborn. Pediatr Res. 1980;14(2):159-63.
Audera GS, EP IC, Eclipse I. Provisional Guidelines for using Auditory Steady State Responses (ASSR) in Babies-A Recommended Test Protocol. 2012.
Berg AL, Spitzer JB, Garvin JH Jr. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope. 1999;109(11):1806-14.
Wilkinson AR, Jiang ZD. Brainstem auditory evoked response in neonatal neurology. In Seminars in Fetal Neonatal Med. 2006;11(6):444-51.
Olusanya BO, Newton VE. Global burden of childhood hearing impairment and disease control priorities for developing countries. Lancet. 2007;369(9569):1314-7.
Rance G, Beer DE, Cone-Wesson B, Shepherd RK, Dowell RC, King AM et al. Clinical findings for a group of infants and young children with auditory neuropathy. Ear Hearing. 1999;20(3):238-52.
Kim LS, Jeong SW, Lee YM, Kim JS. Cochlear implantation in children. Auris Nasus Larynx. 2010;37(1):6-17.